Dr. Mjalli is an internationally recognized entrepreneur in the business of drug discovery and development of new medicines in the pharmaceutical and biotechnology industry. Dr. Mjalli is the founder of TransTech Pharma, LLC and High Point Pharmaceuticals, both of which are drug discovery, development and commercialization companies now under vTv Therapeutics, LLC, High Point Clinical Trials Center (HPCTC) Inc., a clinical trials research and development center that conducts human clinical trials and PharmaCore Inc., a drug manufacturing company. Dr. Mjalli served as Chairman and CEO of TransTech Pharma from December 1998-April 2014. He currently severs as CEO of High Point Clinical Trials Center and Chairman of PharmaCore.

Dr. Mjalli obtained his Ph.D. in Medicinal Chemistry in 1989 from the University of Exeter, UK. His postdoctoral work was carried out at the University of Rochester. Dr. Mjalli has held various positions of increasing responsibility in research and senior management at several pharmaceutical and biotechnology companies including Merck & Co., Inc. and Ontogen Corporation. He is the author of more than 40 scientific papers, four book chapters and an inventor on more than 700 patents and patent applications.

Dr. Mjalli served on the Board of Directors of Siga Technologies, the North Carolina Biotechnology Center, the Guilford Technology Community College (GTCC) Board, and the High Point Economic Development Corporation. Currently, Dr. Mjalli serves on the High Point University Board, The Foundation Board of GTCC, High Point Chamber of Commerce, the Arab American University, the American Task Force on Palestine, the America-Mideast Educational and Training Service, Inc. (AMIDEAST), a member of the American Chemical Society, an honorary fellow of the Islamic World Academy of Sciences, and an honorary member of the Palestine Academy of Science and Technology.

Dr. Mjalli has raised hundreds of millions of dollars for his companies listed above. He has also structured, negotiated, and concluded an excess of a dozen multibillion dollar worth deals with major global pharmaceutical companies.